Fig. 1

Depletion of Sec62 sensitizes CRC cells to chemotherapeutic drugs. a Heatmap showing DEGs in chemoresistant CRCs and chemosensitive CRCs based on dataset GSE28702. b AUC evaluation of prognostic value of candidate genes involved in chemoresistance-related events based on datasets GSE72968 and GSE81005. c The protein level of Sec62 was assessed by Western blot in chemoresistant CRC tissues (R1-R4) and chemosensitive CRC tissues (S1-S4). d Western blot was performed to evaluate Sec62 protein levels in Sec62-depleted DLD1 or HT29 cells. e The cells described in (d) were treated with an increasing concentrations of 5-Fu or oxaliplatin. After 72 h, the viable cells were determined by MTT assay. f The stably transfected cells were treated with 5-Fu or oxaliplatin for 24 h as indicated. The apoptotic cells were determined by flow cytometry using FITC-labeled Annexin V staining. g The stably transfected cells were treated with 5-Fu or oxaliplatin for 48 h. Whole-cell lysates were subjected to Western blot analyses using anti-cleaved caspase 3 (C. CP 3) antibody. β-actin was used as a loading control